Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

27.00 -0.21 (-0.77%)
Streaming Delayed Price Updated: 1:32 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,176
Open 27.01
Bid (Size) 27.00 (1)
Ask (Size) 27.01 (3)
Prev. Close 27.21
Today's Range 26.86 - 27.02
52wk Range 24.53 - 39.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Via Benzinga

Performance

YTD
-15.91%
-15.91%
1 Month
N/A
N/A
3 Month
-8.94%
-8.94%
6 Month
-4.36%
-4.36%
1 Year
-26.53%
-26.53%

More News

Read More
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Via Benzinga
Exposures COVID-19
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB, an undervalued stock with good fundamentals.
Via Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Via Benzinga
Exposures Product Safety
10 Analysts Assess Genmab: What You Need To Know
Via Benzinga
What 9 Analyst Ratings Have To Say About Genmab
Via Benzinga
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
Via Chartmill
7 Stocks That Could Safely 10X by 2030
Via InvestorPlace
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.